P-selectin inhibitor monoclonal antibody
This page covers all P-selectin inhibitor monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting P-selectin.
Targets
Marketed (1)
- Crizanlizumab Injection · Matthew Neal MD · Hematology/Oncology
Crizanlizumab is a monoclonal antibody that binds to P-selectin on the surface of platelets and endothelial cells, blocking platelet-endothelial interactions and reducing vaso-occlusive crises in sickle cell disease.